AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protara Therapeutics, Inc. Director's Dealing 2021

Dec 22, 2021

34057_dirs_2021-12-22_28c1c8ca-a27b-4d36-b4b4-7c1cccc1054c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2021-12-20

Reporting Person: Opaleye Management Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-20	Common Stock, par value $0.001 per share	P	703	$6.49	Acquired	2496209	Indirect

Footnotes

F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.

F2: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume-weighted
average purchase price of $6.49. The range of purchase prices on the transaction date was $6.49 per share.